Baricitinib
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Baricitinib
- Pharmacist Assessment Report
- Baricitinib: JAK1/JAK2 inhibitor → colobomatous microphthalmia-rhizomelic dysplasia syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Baricitinib: JAK1/JAK2 inhibitor → colobomatous microphthalmia-rhizomelic dysplasia syndrome
One-Sentence Summary
Baricitinib is an oral Janus kinase (JAK) inhibitor marketed in Australia. The TxGNN model predicts it may be relevant to colobomatous microphthalmia-rhizomelic dysplasia syndrome, but there are currently no clinical trials and no publications supporting this prediction, so it is a model-based hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for this drug is not available in the data compiled for this report. Baricitinib is generally known as a JAK1/JAK2 inhibitor, which dampens JAK-STAT signalling involved in inflammatory and immune processes.
No mechanistic link between JAK-STAT inhibition and this rare developmental syndrome is supported by the data compiled for this report. The TxGNN score of 0.9994 is a computational prediction only. Such scores can reflect network-level associations rather than validated biology, so this prediction should be treated as hypothesis-generating at most.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11437Y | Olumiant | Tablet 2 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 100 interactions were recorded in the interaction data compiled for this report. Main ones include:
- Major: corticosteroids (hydrocortisone, triamcinolone, betamethasone, budesonide, dexamethasone, prednisolone, prednisone), deferiprone, ibritumomab tiuxetan, iobenguane (I-131) and tositumomab (I-131).
- Moderate: morphine (including liposomal), acetylsalicylic acid, nitisinone and opium.
- Minor: zinc salts (acetate, gluconate, sulfate).
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials, no publications and no established mechanistic link to this syndrome. Evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data and a plausible biological pathway linking JAK-STAT inhibition to this syndrome
- Any preclinical or clinical studies directly addressing this disease
- Review of the TGA Product Information for warnings and contraindications
- Assessment of route and dosage compatibility for this rare congenital condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.